HIV-1 Tat–Env protein–protein interface (Tat–Env PPI)

The HIV-1 Tat–Env protein–protein interface is a functional interaction between the viral Trans-activator of transcription (Tat) and the Envelope (Env) glycoprotein complex. Extracellular Tat, which is actively secreted by infected cells, binds to the Env trimer on the surface of HIV-1 virions, forming a stable complex that enhances viral entry into target cells (Ensoli et al., 2021, Frontiers in Immunology). This interaction also facilitates the delivery of the virus to CD4+ T cells and promotes B-cell activation and dysregulation, contributing to the pathogenesis of HIV-1 (Cafaro et al., 2019, Expert Review of Vaccines). From a therapeutic perspective, the Tat–Env interface is a target for combined vaccine strategies; neutralizing the interaction can prevent the Tat-mediated enhancement of Env-driven infection (Monini et al., 2018, Vaccines). Current research focuses on using this interface to design immunogens that elicit antibodies capable of disrupting the complex, thereby reducing the viral reservoir (Ensoli et al., 2015, Retrovirology). Disrupting this interface may also restore immune function by preventing Tat-induced B-cell hyperactivation and subsequent exhaustion. While no drugs are currently approved specifically for this interface, clinical trials for Tat-based vaccines have shown promise in reducing viral DNA levels in patients on antiretroviral therapy.

Other names

HIV-1 Tat-gp120 complexTat-Env complexHIV-1 Trans-activator of transcription and Envelope glycoprotein interface

Inhibition of the physical interaction between the HIV-1 Tat protein and the Env glycoprotein to prevent enhanced viral entry and immune dysregulation.